Patents by Inventor Yeshwant D. Sanzgiri
Yeshwant D. Sanzgiri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11369599Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.Type: GrantFiled: July 24, 2014Date of Patent: June 28, 2022Assignees: AbbVie Inc., AbbVie Deutschland GMBH & Co KGInventors: Esther Birtalan, Peter Hoelig, David J. Lindley, Yeshwant D. Sanzgiri, Ping Tong
-
Publication number: 20150148331Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.Type: ApplicationFiled: July 24, 2014Publication date: May 28, 2015Inventors: Esther Birtalan, Peter Hoelig, David J. Lindley, Yeshwant D. Sanzgiri, Ping Tong
-
Patent number: 8927009Abstract: A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: GrantFiled: December 21, 2010Date of Patent: January 6, 2015Assignee: AbbVie Inc.Inventors: Ping Tong, Deliang Zhou, Geoff G. Z. Zhang, Katherine R. Heemstra, Cristina M. Fischer, Nathaniel D. Catron, Eric A. Schmitt, Yeshwant D. Sanzgiri
-
Patent number: 8728516Abstract: An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: GrantFiled: April 29, 2010Date of Patent: May 20, 2014Assignee: AbbVie Inc.Inventors: Nathaniel Catron, Michael G. Fickes, Cristina M. Fischer, Anthony R. Haight, Katherine Heemstra, Yeshwant D. Sanzgiri, Eric A. Schmitt, Ping Tong, Geoff G. Z. Zhang, Deliang Zhou
-
Publication number: 20120108590Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.Type: ApplicationFiled: October 5, 2011Publication date: May 3, 2012Applicant: ABBOTT LABORATORIESInventors: Esther Birtalan, Peter Hoelig, David J. Lindley, Yeshwant D. Sanzgiri, Ping Tong
-
Publication number: 20110159085Abstract: A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: ApplicationFiled: December 21, 2010Publication date: June 30, 2011Applicant: ABBOTT LABORATORIESInventors: Ping Tong, Deliang Zhou, Geoff G.Z. Zhang, Katherine R. Heemstra, Cristina M. Fischer, Nathaniel D. Catron, Eric A. Schmitt, Yeshwant D. Sanzgiri
-
Publication number: 20100297194Abstract: An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis-HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier; wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: ApplicationFiled: April 29, 2010Publication date: November 25, 2010Inventors: Nathaniel Catron, Michael G. Fickes, Cristina M. Fischer, Rajeev Gokhale, Anthony R. Haight, Katherine Heemstra, David Hill, Martin Knobloch, Drazen Kostelac, Justin S. Lafountaine, Yanxia Li, Bernd Liepold, Kennan Marsh, Jonathan M. Miller, Claudia Packhaeuser, Yeshwant D. Sanzgiri, Eric A. Schmitt, Yi Shi, Norbert Steiger, Ping Tong, Huailiang Wu, Geoff G.Z. Zhang, Deliang Zhou
-
Publication number: 20100278905Abstract: An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: ApplicationFiled: April 29, 2010Publication date: November 4, 2010Inventors: Nathaniel Catron, Michael G. Fickes, Cristina M. Fischer, Anthony R. Haight, Katherine Heemstra, Yeshwant D. Sanzgiri, Eric A. Schmitt, Ping Tong, Geoff G. Z. Zhang, Deliang Zhou
-
Publication number: 20100280031Abstract: An orally deliverable pharmaceutical composition comprises a drug-carrier system having a Bcl-2 family protein inhibitory compound, e.g., ABT-263, in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: ApplicationFiled: April 29, 2010Publication date: November 4, 2010Inventors: Paul David, Michael G. Fickes, Cristina M. Fischer, Anthony R. Haight, Katherine Heemstra, Kennan Marsh, Peter Mayer, Vitaly Rubin, Yeshwant D. Sanzgiri, Eric A. Schmitt, Ping Tong, Deliang Zhou
-
Patent number: 6838091Abstract: The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in at least one monoglyceride as the primary solvent medium for said agent. One or more emulsifiers may be added to the formulation.Type: GrantFiled: December 18, 1998Date of Patent: January 4, 2005Assignee: Abbott LaboratoriesInventors: John M. Lipari, Dawn M. Raymond, Tom Reiland, Yeshwant D. Sanzgiri
-
Publication number: 20030203931Abstract: Two new crystalline polymorphs of the compound of formula (I) 1Type: ApplicationFiled: April 18, 2003Publication date: October 30, 2003Inventors: John B. Cannon, Pawan Hansrani, Russell L. Hertzler, John M. Lipari, Yeshwant D. Sanzgiri, Steven J. Wittenberger
-
Publication number: 20030199537Abstract: Two new crystalline polymorphs of the compound of formula (I) 1Type: ApplicationFiled: April 18, 2002Publication date: October 23, 2003Inventors: John B. Cannon, Pawan Hansrani, Russell L. Hertzler, John Lipari, Yeshwant D. Sanzgiri, Steven J. Wittenberger
-
Publication number: 20020040046Abstract: The present invention is directed to a formulation comprising a lipid-regulating agent dissolved or dispersed in at least one oil and an emulsifier or emulsifier blend, the resulting mixture being capable of forming an emulsion upon dilution in an aqueous medium.Type: ApplicationFiled: March 13, 2000Publication date: April 4, 2002Inventors: Jitendra P Patel, Yeshwant D Sanzgiri, John M Lipari, Thomas L Reinland
-
Publication number: 20010053385Abstract: The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in at least one monoglyceride as the primary solvent medium for said agent. One or more emulsifiers may be added to the formulation.Type: ApplicationFiled: December 18, 1998Publication date: December 20, 2001Inventors: JOHN M. LIPARI, DAWN M. RAYMOND, TOM REILAND, YESHWANT D. SANZGIRI